ArticleEJNMMI research2026
PET pharmacokinetics of [¹⁸F]F-AraG as a marker of T cell activation during immunotherapy with a STING agonist with and without anti-PD-1.
Article in EJNMMI research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03843359 (A Phase I First Time in Human Open Label Study of GSK3745417 Administered With and Without Anticancer Agents in Participants With Advanced Solid Tumors), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase I First Time in Human Open Label Study of GSK3745417 Administered With and Without Anticancer Agents in Participants With Advanced Solid Tumors
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is an urgent need for clinical biomarkers to monitor the mechanistic efficacy of immunotherapy in oncology. The [
resultsThe kinetics of all tumors and most organs were adequately described with the two-tissue irreversible model (2T3K), which was identified as the preferred model based on the AIC in 40/55 tumor regions. For most organs, the 2T3K model was selected. We observed a consistent linear trend across all metrics for the relationship between primary kinetic parameters and simplified uptake metrics. However, a patient-specific bias can be observed for SUV and TBR, which was corrected for when using the TPR.
conclusionThis study confirms that [
trial registrationClinicalTrials.gov at 14 February 2019, NCT03843359, https//clinicaltrials.gov/study/NCT03843359.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.